Posts With Tag Neurological Disorders

Explore Neurocrine Biosciences' Q4 2024 report highlighting $2.4B in revenue, $341M net income, and key risks. A must-read for investors focused on biopharmaceuticals.

Explore NeuroOne's latest financial performance, growth challenges, and strategic developments. Key insights include a recommended 'Hold' and a revenue surge to $3.27 million.

Explore BioVie Inc.'s financial performance and clinical advancements. Recommendations highlight a 'Hold' position amidst challenges and promising drug developments.